Therapeutic Area

Women's Health

Therapeutic area intelligence for Women's Health with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Fertility →

Network →

Pharmobedient →

Recent signals(4)

RegulatoryJune 21, 2026

FDA Accepts ANDA for Doxylamine Succinate and Pyridoxine Hydrochloride

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Doxylamine Succinate and Pyridoxine Hydrochloride submitted by Pharmobedient.

ClinicalJune 20, 2026

Network meta-analysis compares minimally invasive treatments for uterine fibroids

The analysis evaluates the efficacy and safety of HIFU, RFA, MWA, and UAE against myomectomy for symptomatic uterine fibroids.

ClinicalJune 19, 2026

Study on Resistance Training's Impact on Women's Health During Menopause

A study is investigating the effects of resistance training on blood vessel health and quality of life in women starting menopause.

ClinicalJune 18, 2026

Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health

The inVitD Trial aims to assess the effects of vitamin D supplementation on menstrual cycle hormones in women aged 19-40.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.